COVID19 Vaccine efficacy in oncologic patient. viral vector vaccine , mRAN vaccine cancer patient safety and immunogenicity
Conditions
Interventions
Cancer patients in Thailand who are undergoing treatment and given consent to receive adenovirus vector COVID-19 vaccine
Prevention
Cancer patients
Sponsors
Quality Improvement fund, King chulalongkorn Memorial Hospital,The Thai Red Cross Society
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1) Patients age 18 years old and older 2) Diagnosed with cancer and is undergoing treatment at Chulalongkorn Hospital 3) ECOG Performance status 0-2 4) Has given consent to receiving COVID-19 vaccine 5) Has given consent to participate in the research study
Exclusion criteria
Exclusion criteria: 1) Has histories of allergies (especially allergic reactions to vaccines) 2) Has histories of immune deficiency diseases (e.g. HIV or congenital immune deficiency) 3) Has been infected with COVID-19 within 14 days before receiving the vaccine 4) Has fever higher than 38c within 24 hours before receiving the vaccine 5) Received COVID-19 vaccine before 6) Has histories of hematologic diseases or has limitations for intramuscular injections 7) Has received immunosuppressant drugs unrelated to their cancer treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Antibody response following the third mRNA COVID-19 vaccine in cancer patients 2 week and 12 week after third vaccine Geometric mean titer (GMT) of anti-RBD IgG | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety of third mRNA COVID-19 vaccine 7 days after third dose of mRNA vaccine FDA Toxicity grading scale in preventive vaccine clinical trials,Factors predicting poor immunogenicity 2 weeks after third dose multivariate analysis | — |
Countries
Thailand
Contacts
Public ContactNattaya Teeyapun
Medical oncology unit, faculty of medicine, chulalonkorn University
Outcome results
None listed